New Idea for Cancer Prevention! MySignal Check" to measure DNA damage by urine test goes on sale

Making cancer prevention and early detection more accessible.

Ltd. launched a new product, "My Signal Check," on July 17, 2024 (Wednesday), which tests for DNA damage that accumulates due to lifestyle and other factors, and helps prevent cancer.

What is "My Signal Check"?

MySignal Check" is a urine test that measures DNA damage and evaluates cancer risk. It is believed that DNA is damaged by smoking, drinking, inappropriate lifestyle, stress, and other factors, and that the accumulation of such damage causes abnormal cells to develop and become cancerous.

This test can estimate future cancer risk by measuring how much DNA is currently damaged.

Based on the test results, it is expected that the risk of developing cancer can be reduced by reviewing lifestyle habits.

Features of "My Signal Check

Easy urine test at home

Test results are mailed to your home in about 30 business days.

Results can also be checked online.

One-time and regular courses are available.

Discounts are available for the regular course.

MySignal Check" test procedure

Purchase a test kit

Collect urine at home

Inject urine into the test kit

Send the test kit to Craif's laboratory

Receive the test report by mail in about 30 business days

Results can also be viewed online

New "MySignal ®︎ Membership Plan" is also available!

The "MySignal ®︎ Membership Plan" is a cancer control plan that combines the MySignal ®︎ series of tests to meet your individual needs.

Cancer Control Premium Plan: The highest level plan combining all products in the MySignal ®︎ series

Cancer Risk Early Detection Focused Plan: A plan to understand your cancer risk and monitor risk trends

Cancer Prevention Focused Plan: A plan that supports daily prevention activities while measuring the accumulation of DNA stress after identifying genetic risk and obtaining guidelines for cancer control

MySignal ®︎ series

The MySignal ®︎ Series is a cancer risk test for prevention and early detection.

MySignal Scan: Highly accurate cancer risk assessment test using microRNA x AI

MySignal Lite: A more convenient cancer risk assessment test

MySignal Navi: Cancer-specific genetic test

MySignal Check: Test to monitor and prevent DNA damage

Features of "MySignal ®︎ series

Tests can be performed by simply collecting urine or body fluids without any physical burden.

Supports prevention of disease onset by monitoring DNA damage on a daily basis through 4 tests to know one's constitutional risk

Support for early detection

Cancer prevention and early detection are important for everyone.

MySignal ®︎ series" is a new option to keep cancer away.

About Craif Corporation

■ About Craif

Craif is a Nagoya University venture company founded in 2018. It possesses NANO IP®︎ (NANO Intelligence Platform), a fundamental technology that detects microRNAs and other disease-related biological substances with high accuracy in easily collected body fluids such as urine, etc. Craif is using NANO IP®︎ for early detection of cancer and Craif is using NANO IP to develop tests for the early detection of cancer and personalized medical care.

Company Profile

Company name: Craif Inc.

Representative: Ryuichi Onose, Representative Director

Establishment: May 2018

Capital: 100 million yen (as of March 1, 2024)

Business: Research and development of next-generation tests for early detection of diseases, mainly in the field of oncology, and realization of personalized medicine; provision of next-generation cancer risk test "MySignal ®︎ series

Headquarters: ITP Hongo Office 5F, 2-25-7 Yushima, Bunkyo-ku, Tokyo